Targeted Strategies of Adipose Stem Cells for Metabolic Diseases: Mechanisms and Clinical Translation Challenges.
Chen M., Ding S., Chen W., Chen Y., Li L., He Y.
Clinical Trial on Type 2 Diabetes, Chronic Inflammation, Immune Modulation, published in Stem Cell Rev Rep (2026) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Stem Cell Rev Rep (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42373947
- DOI
- 10.1007/s12015-026-11186-6
Abstract (original English)
Metabolic diseases, such as obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease, and atherosclerosis, represent a growing global health burden. Adipose-derived stem cells (ADSCs) have emerged as promising therapeutic agents due to their multipotency, paracrine activity, and potential for engineering targeted interventions. This review highlights recent advances in targeted ADSC strategies, focusing on their mechanisms, clinical applications, and translational challenges. Key targeted approaches include engineered exosomes for precise immunomodulation, surface-modified ADSCs for enhanced tissue homing, and biomaterial-based delivery systems for sustained and local release. Preclinical studies have demonstrated that these strategies can significantly improve glucose homeostasis, reduce hepatic steatosis, and alleviate chronic inflammation. However, clinical translation faces hurdles, including donor-dependent heterogeneity, a lack of standardized protocols, and insufficient long-term safety data. Future efforts should prioritize the development of precision-targeted ADSC therapies through genetic engineering, functionalized biomaterials, and rigorously controlled clinical trials to fully exploit their potential to treat metabolic diseases.BackgroundMetabolic diseases are prevalent worldwide, with conditions such as metabolic dysfunction-associated steatotic liver
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review
Systematic Review on Type 2 Diabetes, published in Stem Cell Rev Rep (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cell Rev Rep2 citations - Level ASystematic ReviewEurope PMC
Dedifferentiation of Mature Adipocytes and Their Future Potential for Regenerative Medicine Applications
Systematic Review on Type 2 Diabetes, Chronic Wound, published in Biomedicines (2026) — summary generated from the PubMed abstract.
- 2026
Biomedicines - Level ASystematic ReviewEurope PMC
Consolidating Clinical Insights and Uncovering Novel Regulatory Mechanisms of Exosomal MicroRNAs in Obesity and Metabolic Dysfunction Associated Steatotic Liver Disease: A Systematic Review and Bioinformatics Analysis
Systematic Review on Type 2 Diabetes, Chronic Inflammation, published in Food Sci Nutr (2026) — summary generated from the PubMed abstract.
- 2026
Food Sci Nutr - Level AMeta-analysisEurope PMC
Autologous and allogeneic mesenchymal stem cell-based therapies for diabetes mellitus: A systematic review and meta-analysis
Meta-analysis on Type 2 Diabetes, Immune Modulation, published in World J Stem Cells (2025) — summary generated from the PubMed abstract.
- 2025
World J Stem Cells1 citations - Level ASystematic ReviewPubMed
Systematic Review: Exosomes as Molecular Messengers in the Development of Obesity-Related Complications in Children.
Systematic Review on Type 2 Diabetes, published in Curr Issues Mol Biol (2025) — summary generated from the PubMed abstract.
- 2025
Curr Issues Mol Biol - Level AMeta-analysisEurope PMC
Thiamine as a putative natural modulator of PPARγ: exploring a nutrient-based approach for type 2 diabetes
Meta-analysis on Type 2 Diabetes, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol